This is to inform you that Outcome of the Board Meeting of the Company held on today i.e. Thursday 14th May 2026 in accordance with SEBl (Listing Obligations and Disclosures Requirements) ....

Revenue growth above 20%Net loss reportedEBITDA margin compressionNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.3%Reaction day

₹0.61

prior close

₹0.61

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.4%+3.6% vs market

Pharmaceuticals & Biotechnology peers, median of 164sector · industry level-0.2%+3.4% vs sector

On the reaction day the stock moved 3.6 pts more than Nifty Microcap 250 and 3.4 pts more than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

-1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.3-0.4+3.6-0.2+3.4

Next day

-1.6-1.7+0.1-0.9-0.7

-1.6-1.3-0.4-0.2-1.4

+0.0-0.7+0.7+0.2-0.2

-1.6+0.4-2.0+0.7-2.4

-1.6+0.5-2.1+0.2-1.8

-1.6+2.8-4.5+1.0-2.6

15d

-1.6+1.2-2.8-0.2-1.4

+0.0+5.3-5.3+1.5-1.5

-6.6+9.9-16.5+7.7-14.3

-16.4+13.1-29.5+8.1-24.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals & Biotechnology peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shree Ganesh Biotech reported audited standalone financial results for FY ended March 31, 2026. Revenue from operations surged 362% to Rs. 2,295.76 lakhs from Rs. 497.05 lakhs year-on-year. However, profitability declined significantly: PBT fell 25% to Rs. 38.69 lakhs and PAT dropped 26% to Rs. 27.84 lakhs. Total expenses increased sharply to Rs. 2,401.16 lakhs (vs Rs. 592.86 lakhs), primarily driven by material costs of Rs. 2,264.10 lakhs. The statutory auditor issued an Unmodified Opinion (clean audit). The company operates in a single segment with minimal cash reserves (Rs. 0.97 lakhs) despite having substantial loans and investments.

Likely market impact

Revenue growth of 362% is offset by cost escalation and profit decline, indicating margin pressure. Shareholders may be concerned about rising expenses outpacing revenue and minimal cash position despite large revenue scale.